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Background: Language impairment is relatively common in Parkinson’s disease (PD), but not all PD patients are
susceptible to language problems. In this study, we identified among a sample of PD patients those pre-disposed
to language impairment, describe their clinical profiles, and consider factors that may precipitate language disability
in these patients.
Methods: A cross-sectional cohort of 31 PD patients and 20 controls were administered the Chinese version of
the Western Aphasia Battery (WAB) to assess language abilities, and the Montreal Cognitive Assessment (MoCA) to
determine cognitive status. PD patients were then apportioned to a language-impaired PD (LI-PD) group or a PD
group with no language impairment (NLI-PD). Performance on the WAB and MoCA was investigated for correlation
with the aphasia quotient deterioration rate (AQDR).
Results: The PD patients scored significantly lower on most of the WAB subtests than did the controls. The aphasia
quotient, cortical quotient, and spontaneous speech and naming subtests of the WAB were significantly different
between LI-PD and NLI-PD groups. The AQDR scores significantly and positively correlated with age at onset and
motor function deterioration.
Conclusion: A subset group was susceptible to language dysfunction, a major deficit in spontaneous speech.
Once established, dysphasia progression is closely associated with age at onset and motor disability progression.
Keywords: Aphasia quotient, Language function deterioration rate, Language impairment, Parkinson’s disease,
Western aphasia batteryBackground
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by progressive loss of dopaminergic
neurons, primarily in the substantia nigra pars compacta
[1]. Incidence rates of PD increase rapidly in people older
than 60 years [2], and for those older than 55 years the
cumulative risk is 4.9% [3]. PD patients most commonly
present with motor impairments, including the ability to
communicate verbally [4], but problems with cognition
and other systems also occur [5,6]. These can emerge at
any stage of the disease and become worse as the disease
develops, with significant adverse effects on quality of life.* Correspondence: grace_shenyang@163.com
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unless otherwise stated.Language problems afflict the majority of PD patients,
especially in voice and articulation [7]. Spontaneous speech
is severely reduced [8], making verbal communication
slower and less accurate, and deficits in verb inflection
[9,10], verbal fluency [11], and verb generation [12] are
common. The etiology of language deficits in PD is not
definitive; most studies have focused on an association with
handicapped cognition. However, while some researchers
hypothesize that language abilities in PD correlate with
cognitive abilities [13,14], others more specifically connect
language deficits to working memory and executive
function [15]. In addition, clinical observations have
suggested that some degree of depression can affect
language performance. Starkstein et al. [16] found that
patients with major depression performed significantly
worse than non-depressed patients on all aspects of
neuropsychological function tests, including language
tasks. However, another study suggested no difference ins is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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or major depression and the control group [17]. Thus far,
there is no consensus on how major depression affects
language function.
Although language impairment in PD is common, not
all patients are affected, even over the long-term
progression of the disease [18]. The clinical profiles
or features that might differentiate patients who are
predisposed to language impairment have been generally
overlooked, and factors that precipitate language disability
remain elusive. In this study, we wanted to conclude with
a clinical profile of PD patients predisposed to language
impairment, and explore factors related to rapid progression
of language impairment in PD. Therefore, we evaluated the
clinical profiles of PD patients with language impairment
relative to those without impairment, and of healthy
controls, noting differences in demographics, motor
abilities, and cognitive states. We used the Western
Aphasia Battery (WAB) [19], a tool routinely used in




The Ethics Review Board of First Affiliated Hospital of
China Medical University (Shenyang, China) approved
the protocol of the study. Thirty-one PD patients
(18 men and 13 women, aged 63.35 ± 8.84 y) at the
Parkinson’s Disease Outpatient Center of the hospital
were enrolled between May 2013 and October 2013. None
of the patients had a family history of PD, and all met the
criteria for idiopathic PD, according to the UK Parkinson’s
Disease Society Brain Bank clinical diagnostic criteria [22].
All patients were given the best medications for PD. Patients
were excluded if they had clinical features of Parkinson’s-
plus syndrome. None of the patients or their caregivers
complained of obvious cognitive decline in the patients, and
all patients were considered non-demented.
Twenty healthy individuals (age 64.85 ± 8.27 y), most
of whom were spouses of the PD patients and were
comparable for age, gender, and educational level, were
selected as a control group. None of the controls expressed
cognitive complaints or reported a history of neurological
or psychiatric illnesses, and none had a history of severe
cardiovascular, renal, or hepatic disorders. All PD patients
and healthy controls were right-handed.
The 17-item Hamilton Depression Rating Scale
(HAMD-17) [23] was administered to all prospective
participants to identify and measure the severity of
depression symptoms, and individuals with scores >15 were
excluded from the current study.
Demographic data were obtained for each participant,
as well as clinical information consisting of Unified
Parkinson’s Disease Rating Scale (UPDRS) scores, HoehnYahr stage [24] for motor function, and Montreal Cognitive
Assessment (MoCA) [25] scores for cognitive function.
Outcome measures
Defining the type and degree of language impairment in
PD patients is hampered by a lack of generally recognized
clinical criteria. The WAB [19] is an accepted method for
assessing language abilities in many neurological diseases
including stroke [26,27], amyotrophic lateral sclerosis [28],
corticobasal degeneration syndrome [29], and brain
tumor [30]. The WAB aphasia quotient (AQ) provides
a global measure of aphasia severity [31] and was
found appropriate for assessing non-fluent aphasia
[32]. Therefore, we employed the WAB to assess the
language abilities of our subjects.
The WAB includes both linguistic and nonlinguistic
subtests. The former comprises subtests for spontaneous
speech, auditory comprehension, repetition, and naming.
The nonlinguistic portion includes subtests for reading,
writing, praxis, and construction. Based on the results
and the formula (below), the AQ, performance quotient,
and cortical quotient were determined: the AQ reflects
the severity and type of aphasia; the performance quotient
represents the nonlinguistic function of the brain; and
the cortical quotient gives an overall picture of cognitive
status [33].
The AQ (range 0–100) is derived from the linguistic
subtests as follows: AQ = (spontaneous speech score +
auditory comprehension score/20 + repetition score/10 +
naming score/10) × 2. Since there is no standard AQ cutoff
value for PD patients, we used the scores of the control
group to establish a cutoff value. Patients were considered
language impaired if they scored at least two standard
deviations below the mean AQ value for the age- and
education- comparable controls. A similar approach to
setting cutoff points has been used in previous studies to
define impairment in neuropsychological tests [26,27].
Based on the results from the controls, a value of 94.5 was
defined as the cutoff AQ value. AQ values ≥ 94.5 were
considered normal; individuals with scores < 94.5 were
defined as exhibiting language impairment.
To evaluate the rate of decline in language ability of PD
patients, the following formula for the AQ deterioration
rate (AQDR) was applied: AQDR= (94.5 – AQ)/(disease
duration in years). Patients scoring > 94.5 were assigned a
value of exactly 94.5 to avoid negative values. A similar
approach was used previously [26,27,34].
The performance quotient, which combined results of the
reading, writing, praxis, and construction subtests of the
WAB, was used as a reflection of the non-spoken language
function of patients. The cortical quotient was calculated
to represent the general cognitive function, according
to the formula: cortical quotient = (AQ/2) + performance
quotient + (auditory comprehension score/20).
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using Parts II and III of the UPDRS, and cognition
was evaluated by the Beijing version of the MoCA
(the specific test forms and instructions for Beijing
version are available at the MoCA official web-site
http://www.mocatest.org/). The following formula was
used to assess the motor function deterioration rate in
points per year: Motor function deterioration rate, points/
y = (UPDRS III, points)/(disease duration, y). To reduce
the variability in motor function between optimally treated
patients and patients who may have been over- or
under-medicated, the UPDRS rating of each patient
was determined at a time when the patient had been
without PD medications for at least 12 hours.
Statistical analyses
Statistical analyses were performed using the software
program SPSS 17.0 (SPSS, Chicago, IL). Two inde-
pendent sample t-tests for normally distributed variables
(including age, age at onset, HAMD-17 scores, and
MoCA total score), or the Mann–Whitney U test for
non-normally distributed variables, were used to assess
the differences between the PD and control groups, and
between the language-impaired PD (LI-PD) and no
language impairment PD (NLI-PD) groups. Linguistic
features of the LI-PD, NLI-PD, and control groups
were analyzed using analysis of variance by setting the




Age, y 63.35 ±
Formal education, y 10.74 ±
MoCA total scores 21.00 ±
HAMD-17 score 8.42 ±






Praxis and construction 80.81 ±
Aphasia quotient 93.11 ±
Score < 94.5, n (%) 17 (54
Performance quotient 34.67 ±
Cortical quotient 91.03 ±
aData are expressed as numbers or as mean ± standard deviation, with percentages
Levene’s test for equality of variances: MoCA total score F = 8.14, P = 0.007; Spontan
F = 13.52, P = 0.001; Praxis and construction F = 2.40 P = 0.129; Aphasia quotient F =
F = 6.57 P = 0.014.Univariate and multivariate regression analyses were
performed to determine the association between AQDR
and the demographic and motor features of PD patients,
and between the AQ and cognitive status as evaluated
by MoCA. Results are reported as mean ± standard
deviation. Values of P < 0.05 were considered statistically
significant.
Results
Language abilities of PD patients were impaired
compared with controls
The language abilities of the 31 PD patients and 20
controls were assessed using the WAB (Table 1). The
mean AQ score of the PD group (93.11 ± 4.55) was
significantly lower than that of the control group
(98.07 ± 1.75; P < 0.001). In addition, the PD patients
scored significantly lower on some of the subtests of
the WAB (P < 0.05), namely those for spontaneous
speech, repetition, writing, praxis and construction,
performance quotient, and cortical quotient.
Demographic features and MoCA performance in PD
patients with and without language impairment
Seventeen of the PD patients (54.8%) scored ≥2 standard
deviations below the control mean AQ value (cutoff
value = 94.5) and therefore comprised the LI-PD group
(Table 2). The remaining PD patients (n = 14; 45.2%) had




8.84 (44–77) 64.85 ± 8.27 (51–76) 0.543
3.08 10.95 ± 2.69 0.800
4.341 25.80 ± 1.642 0.000d
2.29 7.45 ± 2.44 0.157
1.92 19.75 ± 0.55 0.000d
± 8.45 194.50 ± 2.80 0.656
4.71 97.70 ± 3.37 0.000d
4.62 98.30 ± 2.27 0.078
9.20 95.85 ± 7.05 0.061
13.92 89.80 ± 5.98 0.000d
9.76 87.80 ± 7.45 0.013e
4.55 (81.9-99.3) 98.07 ± 1.75 (95.9-100.0) 0.000d
.8%) 0 (0%) NA
2.65 37.26 ± 1.65 0.001d
4.68 96.07 ± 2.47 0.000d
or ranges in parentheses; bn = 31; cn = 20; dP < 0.01; eP < 0.05.
eous speech F = 13.76, P = 0.001; Repetition F = 2.52 P = 0.119; Writing
13.65 P = 0.001; Performance quotient F = 2.59 P = 0.106; Cortical quotient







P, LI-PD cf. NLI-PD P, LI-PD cf. control P, NLI-PD cf. control
Men 12 6 12 0.157 0.731 0.487
Women 5 8 8
Age, y 63.59 ± 8.62 63.07 ± 9.43 64.85 ± 8.27 0.843 0.653 0.564
Age at onset, y 55.06 ± 10.92 56.36 ± 10.95 NA 0.781 NA NA
Formal education, y 10.53 ± 2.67 11.00 ± 3.60 10.95 ± 2.69 0.780 0.637 0.983
Disease duration, y 8.53 ± 4.49 6.71 ± 3.29 NA 0.327 NA NA
Hoehn-Yahr stage 2.50 ± 0.55 2.57 ± 0.39 NA 0.415 NA NA
UPDRS part II 15.69 ± 8.39 11.79 ± 4.87 NA 0.138 NA NA
UPDRS part III 38.87 ± 12.11 32.86 ± 8.76 NA 0.135 NA NA
HAMD-17 scores 8.88 ± 2.34 7.86 ± 2.18 7.45 ± 2.44 0.691 0.208 1.000
MoCA scores 19.60 ± 4.75 22.75 ± 3.14 25.80 ± 1.64 0.142 0.000b 0.021b
aData are expressed as numbers or mean ± standard deviation; NA = Not applicable; LI-PD = language impairment Parkinson’s disease; NLI-PD = no language
impairment Parkinson’s disease; cf. = confer (compare); bP < 0.05.
F value of MoCA scores between groups is 15.32, and P value is 0.000.
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was found between the LI-PD and NLI-PD patients,
including age, age at onset, level of education, disease
duration, Hoehn-Yahr stage, UPDRS part II and part III
scores, and HAMD-17 scores. This suggests that the
influence of demographics on the incidence of language
impairment in PD was minimal.
We also assessed differences in the characteristics of
language function between the LI-PD and NL-PD groups
as evaluated by the WAB (Table 3). We set the MoCA
score as a covariant to exclude the influence of cognitive
state. The result showed that between the LI-PD and
NLI-PD groups the differences were significant with
regard to AQ, cortical quotient of the WAB, and the
scores of the spontaneous speech and naming subtests
of the WAB. No significance was found between the
NLI-PD group and the controls. These results suggest
that the language abilities and clinical profiles of PD
patients without language impairment are basically
the same as those of the controls, and the language
impairments measured for PD patients as a single group
are mainly due to the subset of PD patients prone to
having language deficits. Thus language deficits are
unique to this subset of PD patients.
Language deficit is a feature independent of the
cognitive state in LI-PD patients
The MoCA is a sensitive method for measuring cognitive
function in PD patients, with good intra-class correlation
and inter-rater reliability [25,35]. To clarify whether
language disorder is associated with cognitive impairment,
we compared the MoCA scores of all the groups, and also
analyzed the degree of correlation in language impairment
PD patients between AQ and MoCA scores or its subtests
(Table 4).Our results showed that the MoCA scores of both
PD groups were significantly lower compared with
the controls (Table 2), while the differences in cognitive
ability were not significantly different between the LI-PD
and NLI-PD groups. This implies that even though
language is a component of cognition, PD-related
language impairment is a specifically isolated feature
independent of overall cognitive status. The conclusion
was further supported by the finding that among LI-PD
patients, there was no significant correlation between
the total MoCA score (or each of the MoCA subsets)
and AQ (Table 4).
We also investigated whether a correlation exists
between depression and language function in PD
patients, and found no significant correlation (data
not shown).
Later age at onset is an independent risk factor for faster
language dysfunction in LI- PD patients
To determine risk factors that influence the rate of
language decline in PD patients, we used univariate
or multivariate regression model analysis of the available
clinical features of the 17 LI-PD patients (i.e., AQ ≤ 94.5).
The parameters consisted of age at onset, education,
disease duration, Hoehn-Yahr stage, and MoCA total
score. Univariate linear regression analysis showed
that the AQDR correlated significantly with both age
at onset (B = 0.036, P = 0.037) and the deterioration
rate of motor function (B = 0.167, P = 0.006). How-
ever, subsequent multivariate regression analysis
revealed that only the age at onset was an independ-
ent factor for faster deterioration of language ability
(B = 0.036, P = 0.037). Thus, the older the patient at
PD onset, the faster language dysfunction progressed
(Table 5).
Table 3 Characteristics of language function in LI-PD, NLI-PD and control groupsa












Spontaneous speech 17.06 ± 1.92 19.57 ± 0.51 19.75 ± 0.55 24.343 (1, 28) 0.000e 28.736 (1, 34) 0.000e 0.250 (1, 31) 0.621
Auditory
comprehension
189.24 ± 9.26 195.14 ± 5.83 194.50 ± 2.80 2.271 (1, 28) 0.143 0.965 (1, 34) 0.333 0.377 (1, 31) 0.544
Repetition 92.00 ± 4.96 92.79 ± 4.51 97.70 ± 3.37 0.218 (1, 28) 0.644 3.636 (1, 34) 0.065 3.657 (1, 31) 0.065
Naming 94.06 ± 5.06 98.29 ± 2.70 98.3 ± 2.27 4.258 (1, 28) 0.048e 5.238 (1, 34) 0.032e 0.606 (1, 31) 0.442
Reading 89.20 ± 9.25 92.75 ± 9.24 95.8 ± 7.05 0.556 (1, 28) 0.465 1.102 (1, 34) 0.303 0.017 (1, 31) 0.897
Writing 69.75 ± 10.86 78.51 ± 15.33 89.80 ± 5.98 1.877 (1, 28) 0.187 13.410 (1, 34) 0.001e 1.824 (1, 31) 0.187
Praxis and
construction
78.44 ± 9.28 82.58 ± 10.13 87.8 ± 7.45 0.506 (1, 28) 0.486 0.392 (1, 34) 0.537 0.013 (1, 31) 0.908
Aphasia
quotient
89.97 ± 3.69 96.94 ± 1.47 98.07 ± 1.75 34.835 (1, 28) 0.000e 36.259 (1, 34) 0.000e 0.434 (1, 31) 0.515
Performance
quotient
33.83 ± 2.06 35.30 ± 2.94 37.26 ± 1.65 1.142 (1, 28) 0.299 5.294 (1, 34) 0.030e 0.407 (1, 31) 0.528
Cortical quotient 87.88 ± 4.20 93.40 ± 3.57 96.07 ± 2.47 9.945 (1, 28) 0.005e 14.206 (1, 34) 0.001e 0.483 (1, 31) 0.493
aData are expressed as numbers or mean ± standard deviation; bn = 17; cn = 14; dn = 20; eP< 0.05.
LI-PD = langue impairment Parkinson disease; NLI-PD = no language impairment Parkinson’s disease; cf. = confer (compare); df = degree of freedom.
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Recognizing that not all PD patients suffer from
language disabilities, in the present study we
attempted to characterize the subset of PD patients
who do suffer verbal communication problems and
determine factors that influence their susceptibility
and rate of language deterioration. We found that
the language abilities of the PD patients, as a group,
had suffered relative to those of the healthy controls
comparable for education and age. However, further
investigation showed that findings regarding language
impairment were based predominantly on a subset of
PD patients considered LI-PD by the WAB scores,Table 4 Correlation of AQ and MoCA scores for LI-PD
patients
MoCA score r P-value
Total 0.027 0.923
Lines −0.077 0.785
Copy cube 0.098 0.728
Clock drawing test −0.012 0.967
Naming −0.164 0.560
Digit span forward 0.023 0.938
Digit span backward 0.140 0.620
Alertness −0.174 0.534
Calculation −0.258 0.354
Language repeat 0.392 0.148
Verbal fluency 0.314 0.254
Abstraction −0.139 0.622
Delayed recall 0.042 0.881
Orientation −0.289 0.296
LI-PD = language impairment Parkinson’s disease.while the linguistic profiles of the remaining NLI-PD
patients and controls were virtually identical. Furthermore,
the language disorder of the LI-PD patients was inde-
pendent of their cognitive status, suggesting a unique
mechanism underlying language disorder in PD. We
also determined that later age at onset was a risk factor
for faster language deterioration.
The spontaneous speech subtest of the WAB accounts
for 40% of the WAB assessment, and is an evaluation of
information content and fluency [36]. A maximum score
requires normal fluency and complete content, without
hesitations or difficulties finding words, despite the
anxiety of being tested. The poor performance of PD
patients on the spontaneous speech portion of the
WAB reflects their difficulty expressing themselves
verbally. In the present study the spontaneous speech
measure was the most important for discriminating
the LI-PD and NLI-PD patients, as it accounted for
70% of the difference between the two groups; the
scores between the NLI-PD patients (19.57 ± 0.51) and
controls (19.75 ± 0.55) were virtually identical (P = 1.000).
This suggests that as the most discriminating indicator
of language disability, the spontaneous speech score is
also the most sensitive for revealing language impairment
in the subset of PD patients susceptible to language
dysfunction.
In our study, the total MoCA score for all the PD
patients together was significantly lower than that of
the controls. This is consistent with the commonly
recognized prevalence of cognitive impairment in PD
[37]. Many studies have shown that impairments in
cognitive ability could influence language function
[13,14,38]. Based on this reasoning, we analyzed the
correlation between cognition and language function.
Table 5 Correlation of AQDR with demographic features of LI-PD patients
Univariate analysis Multivariate analysis
B (95% CI) F (df) P-value B (95% CI) F (df) P-value
Age at onset, years 0.036 (0.002, 0.069) 5.463 (1, 15) 0.037* 0.036 (0.002-0.069) 5.463 (1, 15) 0.037*
Motor function deterioration rate 0.167 (0.056, 0.278) 10.973 (1, 15) 0.006*
Education, years −0.015 (−0.173, 0.144) 0.037 (1, 15) 0.846
Hoehn-Yahr stage 0.188 (−0.620, 0.997) 0.259 (1, 15) 0.625
MoCA total score 0.012 (−0.090, 0.115) 0.069 (1, 15) 0.797
LI-PD = language impairment Parkinson’s disease; CI = confidence interval; df = degree of freedom; *P < 0.05.
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patients were similar, and for the LI-PD there was no
correlation between the AQ and MoCA scores (or
between the AQ and any of the MoCA subtests).
Therefore, even though language is a component of
cognition, language dysfunction in PD is not associated
with cognitive status, but rather is a relatively unique
feature of a subset of PD patients predisposed to language
problems.
This suggests that cognition is not the primary factor
influencing language impairment, but that other factors
are involved, or language impairment is simply due to
the nature of the disease. Altmann and Troche [15] also
concluded that there may be neural circuits, primarily
used in language production, that are independently
damaged in PD.
The pathophysiology that leads to language disorders
may develop as Parkinson’s disease progresses, but for
non-susceptible PD patients language ability may be kept
relatively intact. Interestingly, the mean MoCA score of
the healthy controls was only 25.8 ± 1.64, with 55%
scoring less than 26. This is in accord with our previous
study [34]. Through interviews with the families, we
confirmed the healthy cognitive state of all our 20
controls. We thus conclude that 26 should not be a
cutoff value in our group and attribute this difference
to the different cultural background of these patients. In
some studies, even lower MoCA scores for the controls
were reported [39].
To identify risk factors for PD patients with language
impairment, we compared the demographic features of
LI-PD and NLI-PD patients. We found no significant
differences between these groups with regard to age, age
at onset, level of education, disease duration, or disease
severity. This is similar to the results of Miller et al. [40].
While we contend that there is a discrete subset of PD
patients susceptible to language deficits, even within the
LI-PD group the rate progression of language disability
varied widely, making risk factors difficult to determine.
We thus continued to investigate the factors that influenced
the rate of deterioration in the LI-PD patients, as reflected
by the AQDR. The univariate linear regression analysis
showed that AQDR correlated significantly with both ageat onset (B = 0.036, P = 0.037) and the deterioration rate of
motor function (B = 0.167, P = 0.006). However, according
to the multivariate regression analysis, only age at onset
was a significant risk factor. Therefore, for the language-
impaired PD patient, age at onset of PD is an independent
risk factor for the deterioration rate in language ability; that
is, the later the age at onset of PD, the faster the rate of
language dysfunction. This is in accord with a study
by Locascio et al. [41], in which language deterioration in
PD was related to late onset of the disease only. Yet, our
study went a step further and isolated late onset as an
independent risk factor.
In general, later-onset PD patients have faster motor
deterioration, more severe motor symptoms, and rapid
cognitive impairment [34,42-46]. Some researchers have
speculated that, unlike older patients, those younger have
functional reserves that can compensate for impairments
in certain other functions [47], which explains the effects
associated with late onset of PD. Functional neuroimaging
studies in healthy young and older participants indicate
that older people have more bilateral activation [48]. Two
theories are cited to explain this finding: dedifferentiation
of activation or compensatory activation in older people.
The dedifferentiation theory posits that older persons have
difficulty recruiting specialized neural mechanisms. The
compensatory hypothesis asserts that older persons
employ homologous lateral structures to bolster impaired
processing.
The design of the present pilot study imposed some
limitations on its findings. Firstly, the MoCA provides only
a rough estimate of cognitive function compared with other
cognitive scales, and may not provide a full and accurate
assessment of each of the cognitive domains. Secondly, we
used the equation AQDR= (94.5 – AQ)/(disease duration
in years) to calculate the AQ deterioration rate in patients
with PD. Indeed, AQDR is unable to truly reflect the pat-
tern of deterioration in patients’ language function, but only
the average rate of deterioration. Long-term follow-up of
patients is essential for the study of the pattern of language
function deterioration. Thirdly, as an explorative study that
relied on small and convenient samples, the subjects may
not be representative of the general PD population, and lar-
ger samples are required to confirm or modify our results.
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assessment of factors influencing language impairment in
PD. Yet, our results strongly indicate that language
disability in PD applies only to a distinct subset of PD
patients, and late onset is an independent risk factor.
Identifying the PD patients who are at high risk of
language dysfunction and establishing the factors that
influence language disorder, is important for improving
the quality of life of these patients.
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